Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as flutamide, bicalutamide, leuprolide, buserelin, and goserelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving androgen suppression therapy together with radiation therapy is more effective with or without docetaxel in treating prostate cancer. PURPOSE: This randomized phase III trial is studying androgen suppression therapy, radiation therapy, and docetaxel to see how well they work compared with androgen suppression therapy and radiation therapy in treating patients with high-risk localized prostate cancer. CLOSURE: This trial closed to further accrual in November 2009. The study endpoints will not be reached.
Timeline
- Start
- 2008-06-02
- Primary completion
- 2010-05-14
- Completion
- 2011-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Comparator | Bicalutamide | Other / unclassified | — | Oral |
| Comparator | Goserelin | Other / unclassified | — | Subcutaneous |
| Comparator | Leuprolide | Other / unclassified | — | Subcutaneous |
| Comparator | buserelin | Unknown | — | Subcutaneous |
| Comparator | flutamide | Small molecule | — | Oral |